Human pericoronary adipose tissue as storage and possible supply site for oxidized low-density lipoprotein and high-density lipoprotein in coronary artery

Journal of Cardiology

Volumn 69, Issue 1, 2017, Pages 236-244

  Uchida, Yasumi ^a,b   Uchida, Yasuto ^c   Shimoyama, Ei ^d   Hiruta, Nobuyuki ^e   Kishimoto, Toshihoko ^f   Watanabe, Soichiro ^f  

^a The Japan Foundation   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tsukuba Memorial Hospital   (Japan)

^d Funabashi Futawa Hospital   (Japan)

^e TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^f TOHO UNIVERSITY   (Japan)

Author keywords

Human coronary plaques; Immunohistochemical staining; Low density lipoprotein; Pericoronary adipose tissue; Vasa vasorum

Indexed keywords

CD31 ANTIGEN; CD68 ANTIGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADIPOSE TISSUE; ADULT; ADVENTITIA; ANGIOSCOPY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PERICORONARY ADIPOSE TISSUE; PROTEIN LOCALIZATION; TISSUE PRESERVATION; VASA VASORUM; ATHEROSCLEROTIC PLAQUE; AUTOPSY; CHEMISTRY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; INTIMA; MACROPHAGE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADIPOSE TISSUE; ANGIOSCOPY; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; AUTOPSY; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; TUNICA INTIMA; VASA VASORUM;

EID: 84969270829     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2016.03.015     Document Type: Article

References (30)

1. [1] Szasz, T., Webb, C., Perivascular adipose tissue: more than just structural support. Clin Sci 122 (2012), 1–12.
2. [2] Lee, D.E., Kehlenbrink, S., Lee, H., Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab 296 (2009), E1210–E1229.
3. [3] Shibata, R., Ouchi, N., Murohara, T., Adiponectin and cardiovascular disease. Circ J 73 (2009), 608–614.
4. [4] Anger, F.A., D'Orleans-Juste, P., Germain, L., Adventitia contribution to vascular contraction: hints provided by tissue-engineered substitutes. Cardiovasc Res 75 (2007), 669–678.
5. [5] Miao, C.Y., Li, Z.Y., The role of perivascular adipose tissue invascular smooth muscle cell growth. Br J Pharmacol 165 (2012), 643–658.
6. [6] Aghamohammadzadeh, R., Witners, S., Lynch, F., Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol 165 (2012), 670–682.
7. [7] Gollasch, M., Vasodilator signals from perivascular adipose tissue. Br J Pharmacol 165 (2012), 633–642.
8. [8] Barton, M., Baretella, O., Meyer, M., Obesity and risk of vascular disease: importance of endothelium-dependent vasocostriction. Br J Pharmacol 165 (2012), 591–602.
9. [9] Payne, G., Kohr, M., Tune, J., Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease. Br J Pharmacol 165 (2012), 659–669.
10. [10] Shah, P.K., Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 23 (2009), 31–40.
11. [11] Chen, J.H., Riazzy, M., Smith, E.M., Oxidized LDL-mediated macrophage survival involves elongation factor-2 kinase. Arterioscler Thromb Vasc Biol 29 (2009), 92–98 2009;119:136–45.
12. [12] Volvoet, P., Oxidized LDL and coronary heart disease. Acta Cardiol 59 (2004), 479–484.
13. [13] Takahashi, K., Takeya, M., Sakashita, N., Multifunctional roles of macrophages in the development and progression of atherosclerosis in human and experimental animals. Med Electron Microsc 35 (2002), 179–203.
14. [14] Assmann, G., Schalte, H., von Ecckardstein, A., High-density lipoprotein cholesterol as a predictors of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124:Suppl (1996), S11–S20.
15. [15] Toh, P.P., Davidson, M.H., High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol 4 (2010), 359–364.
16. [16] Cho, K.H., Biomedical implications of high-density lipoprotein: its composition, structure, functions, and clinical applications. BMB Rep 42 (2009), 393–400.
17. [17] Uchida, Y., Angioscopes and its manipulation. Uchida, Y., (eds.) Coronary angioscopy, 2001, Futura Publishing LTD, Armonk, NY, 11–24.
18. [18] Uchida, Y., Clinical classification of atherosclerotic coronary. Uchida, Y., (eds.) Coronary angioscopy, 2001, Futura Publishing Ltd, Armonk, NY, 71–81.
19. [19] Uchida, Y., Uchida, H., Kawai, S., Detection of vulnerable coronary plaques by color fluorescent angioscopy. JACC Cardiovasc Imaging 3 (2010), 398–408.
20. [20] Yamada, H., Sata, M., Role of pericardial fat. The good, the bad and the ugly. J Cardiol 65 (2015), 2–4.
21. [21] Boyd, H.C., Gown, A.M., Wolfbauer, G., Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 135 (1989), 815–825.
22. [22] de Paoli, F., Stales, B., Chinetti-Gbaguidi, G., Macrophage phenotypes and their modulation in atherosclerosis. Circ J 78 (2014), 1775–1781.
23. [23] Holness, C.L., Simmons, D.L., Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 18 (1993), 1607–1613.
24. [24] Bonne, D., Heusele, C., Simon, C., Pantaloni, D., 4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules. J Biol Chem 260 (1985), 2819–2825.
25. [25] Rader, D.J., Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116 (2006), 3090–3100.
26. [26] Libby, P., The vascular biology of atherosclerosis. Mann, D.L., Zipes, D.P., Libby, P., Bonow, R.O., Braunwald, E., (eds.) Heart disease, 10th ed., 2015, Elsevier Saunders Ltd, Philadelphia, 873–890.
27. [27] Yoshida, H., Kisugi, R., Mechanisms of LDL oxidation. Clin Chim Acta 411 (2011), 1875–1882.
28. [28] Sugiyama, S., Kuriyama, K., Aikawa, M., Nakamura, S., Ogawa, H., Libby, P., Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque and thrombogenesis. Arterioscler Thromb Vasc Biol 24 (2004), 139–145.
29. [29] Lancelloti, P., Pierard, L.A., Scheen, A.J., Acute coronary syndrome and lipid-lowering therapy. Does the IMPROVE-IT study make any difference?. Rev Med Liege 70 (2015), 450–455.
30. [30] Tsujita, K., Sugiyama, S., Sumida, H., Impact of dual lipid-lowering strategy with ezetimibe and atorovastatin on coronary plaque regression in patients with percutaneous intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 66 (2015), 495–507.